These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34752901)

  • 21. Vancomycin Treatment Alters Humoral Immunity and Intestinal Microbiota in an Aged Mouse Model of Clostridium difficile Infection.
    van Opstal E; Kolling GL; Moore JH; Coquery CM; Wade NS; Loo WM; Bolick DT; Shin JH; Erickson LD; Warren CA
    J Infect Dis; 2016 Jul; 214(1):130-9. PubMed ID: 26917573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter study of the epidemiology of Clostridioides difficile infection and recurrence in southern Brazil.
    Maestri AC; Raboni SM; Morales HMP; Ferrari LF; Tuon FFB; Losso A; Marconi C; Nogueira KDS
    Anaerobe; 2020 Aug; 64():102238. PubMed ID: 32717474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Host Immune Response to Clostridium difficile Infection in Inflammatory Bowel Disease Patients.
    Hughes M; Qazi T; Berg A; Weinberg J; Chen X; Kelly CP; Farraye FA
    Inflamm Bowel Dis; 2016 Apr; 22(4):853-61. PubMed ID: 26954708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of the humoral immune response to Clostridium difficile toxins A and B in susceptibility to C. difficile infection: a case-control study.
    Islam J; Taylor AL; Rao K; Huffnagle G; Young VB; Rajkumar C; Cohen J; Papatheodorou P; Aronoff DM; Llewelyn MJ
    Anaerobe; 2014 Jun; 27():82-6. PubMed ID: 24708941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and verification of an enzyme-linked immunosorbent assay for the quantification of toxoid A and toxoid B from Clostridioides difficile.
    Anwar S; Bryan D; Rigsby P; Dougall T; Rijpkema S
    J Immunol Methods; 2021 Jan; 488():112917. PubMed ID: 33221460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inflammasome activation contributes to interleukin-23 production in response to Clostridium difficile.
    Cowardin CA; Kuehne SA; Buonomo EL; Marie CS; Minton NP; Petri WA
    mBio; 2015 Jan; 6(1):. PubMed ID: 25626905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human C. difficile toxin-specific memory B cell repertoires encode poorly neutralizing antibodies.
    Shah HB; Smith K; Scott EJ; Larabee JL; James JA; Ballard JD; Lang ML
    JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32663199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of poor outcome in Clostridioides difficile infection: A multicentre external validation of the toxin B amplification cycle.
    Reigadas E; Alcalá L; Marín M; Martin A; Muñoz P; Bouza E;
    Anaerobe; 2020 Feb; 61():102079. PubMed ID: 31356959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic value of toxin B and binary toxin in
    López-Cárdenas S; Torres-Martos E; Mora-Delgado J; Sánchez-Calvo JM; Santos-Peña M; Zapata López Á; Dolores López-Prieto M; Pérez-Cortés S; Carlos Alados J
    Gut Microbes; 2021; 13(1):1884516. PubMed ID: 33660568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI.
    Finn E; Andersson FL; Madin-Warburton M
    BMC Infect Dis; 2021 May; 21(1):456. PubMed ID: 34016040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clostridioides difficile infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study.
    Blumberg EA; Collins G; Young JH; Nguyen MH; Michonneau D; Temesgen Z; Origȕen J; Barcan L; Obeid KM; Belloso WH; Gras J; Corbelli GM; Neaton JD; Lundgren J; Snydman DR; Molina JM;
    Transpl Infect Dis; 2022 Feb; 24(1):e13770. PubMed ID: 34821423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection.
    Warny M; Vaerman JP; Avesani V; Delmée M
    Infect Immun; 1994 Feb; 62(2):384-9. PubMed ID: 8300199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The association of a reduced susceptibility to moxifloxacin in causative Clostridium (Clostridioides) difficile strain with the clinical outcome of patients.
    Krutova M; Capek V; Nycova E; Vojackova S; Balejova M; Geigerova L; Tejkalova R; Havlinova L; Vagnerova I; Cermak P; Ryskova L; Jezek P; Zamazalova D; Vesela D; Kucharova A; Nemcova D; Curdova M; Nyc O; Drevinek P
    Antimicrob Resist Infect Control; 2020 Jun; 9(1):98. PubMed ID: 32605598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Cycle Threshold, Toxin Concentration, and Clinical Characteristics of Clostridioides difficile Infection in Patients with Discordant Diagnostic Test Results.
    Shah MD; Balada-Llasat JM; Coe K; Reed E; Sandlund J; Pancholi P
    J Clin Microbiol; 2020 Apr; 58(5):. PubMed ID: 32051264
    [No Abstract]   [Full Text] [Related]  

  • 35. Protective antibodies against Clostridium difficile are present in intravenous immunoglobulin and are retained in humans following its administration.
    Negm OH; MacKenzie B; Hamed MR; Ahmad OAJ; Shone CC; Humphreys DP; Ravi Acharya K; Loscher CE; Marszalowska I; Lynch M; Wilcox MH; Monaghan TM
    Clin Exp Immunol; 2017 Jun; 188(3):437-443. PubMed ID: 28213939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitive assays enable detection of serum IgG antibodies against Clostridium difficile toxin A and toxin B in healthy subjects and patients with Clostridium difficile infection.
    Zhao X; Bender F; Shukla R; Kang JJ; Caro-Aguilar I; Laterza OF
    Bioanalysis; 2016 Apr; 8(7):611-23. PubMed ID: 26964649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls.
    Sánchez-Hurtado K; Corretge M; Mutlu E; McIlhagger R; Starr JM; Poxton IR
    J Med Microbiol; 2008 Jun; 57(Pt 6):717-724. PubMed ID: 18480328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective efficacy induced by recombinant Clostridium difficile toxin fragments.
    Leuzzi R; Spencer J; Buckley A; Brettoni C; Martinelli M; Tulli L; Marchi S; Luzzi E; Irvine J; Candlish D; Veggi D; Pansegrau W; Fiaschi L; Savino S; Swennen E; Cakici O; Oviedo-Orta E; Giraldi M; Baudner B; D'Urzo N; Maione D; Soriani M; Rappuoli R; Pizza M; Douce GR; Scarselli M
    Infect Immun; 2013 Aug; 81(8):2851-60. PubMed ID: 23716610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clostridioides difficile exploits toxin-mediated inflammation to alter the host nutritional landscape and exclude competitors from the gut microbiota.
    Fletcher JR; Pike CM; Parsons RJ; Rivera AJ; Foley MH; McLaren MR; Montgomery SA; Theriot CM
    Nat Commun; 2021 Jan; 12(1):462. PubMed ID: 33469019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Humoral Immune Response to
    Alonso CD; Papamichael K; Sprague R; Barrett C; Gonzales-Luna AJ; Daugherty K; Garey KW; Villafuerte-Gálvez J; Xu H; Lin Q; Wang L; Chen X; Pollock NR; Kelly CP
    Open Forum Infect Dis; 2021 Jul; 8(7):ofab286. PubMed ID: 34258317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.